← Back to patent-cliff list
NBI-1117570
Tier C — Watch / tradeNBI-1117570
Nxera Pharma Co Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CHRM1, CHRM4
Indications (approved)：Schizophrenia, 神经疾病
Regional status
US
Phase I
2023-09-11
EU
Phase II
2026-02-16
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of NBI-1117570?
Approved indications include: Schizophrenia, 神经疾病.
When does the NBI-1117570 patent expire?
No public expiry year is available for NBI-1117570 yet; this page updates once verified.
How do I get a quote for NBI-1117570 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29